Professor of Medicine, Wake Forest University Baptist Medical Center and Health Sciences, Winston-Salem, North Carolina; Director, Hepatobiliary and Pancreatic Disorders Service, Baptist Medical Center, Winston-Salem, North Carolina

John Baillie, MB, ChB, FRCP, FASGE, has disclosed that he has served as an advisor or consultant to ConMed and Cook, Inc. and served on the speaker's bureau for Astra-Zeneca and as a drug safety monitor for GlaxoSmithKline. Dr. Baillie has also disclosed that he has received grants for clinical research from Pentax US (Instruments).

Clinical Associate Professor of Medicine, Drexel University College of Medicine; Chief, Division of Internal Medicine, Frankford Hospitals, Thomas Jefferson University Healthcare System, Philadelphia Pennsylvania

Geoffrey L. Braden, MD, has disclosed that he has received grants for clinical research from Proctor and Gamble. Dr. Braden has also disclosed that he has served on speaker's bureaus for Proctor and Gamble, AstraZeneca, and TAP Pharmaceuticals.

Director of Endoscopy, Department of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts

David L. Carr-Locke, MD, has disclosed that he has received royalties from US Endoscopy and Telemed and has received research grants from Boston Scientific and ConMed.

Professor of Medicine and Clinical Pharmacology; Chief, Section of Gastroenterology, University of Chicago, Chicago, Illinois

Stephen Hanauer, MD, has disclosed that he has received grants for clinical research from Abbott, Centocor, UCB, Proctor & Gamble, Shire, Salix, Elan, and Prometheus Labs. Dr. Hanauer has also disclosed that he has received grants for educational activities from Abbott, Centocor, UCB, Proctor & Gamble, Shire, Salix, Elan, Prometheus Labs, and TAP and has served as an advisor or consultant to Abbott, Centocor, UCB, Proctor & Gamble, Shire, Salix, Elan, Prometheus Labs, and McNeil.

Professor of Medicine, Chief of Gastroenterology, Eastern Virginia School of Medicine, Norfolk, Virginia

David A. Johnson, MD, FACG, FACP, has disclosed that he has served as a consultant to AstraZeneca, TAP, and Novartis. Dr. Johnson has also disclosed that he has received research grants from AstraZeneca and Novartis.

Chair, Division of Gastroenterology, Albert Einstein Medical Center, Philadelphia, Pennsylvania

Philip Katz, MD, his disclosed that he has received grants or funds from AstraZeneca, and has received honoraria for lectures from AstraZeneca, Santarus, and TAP. Dr. Katz has also disclosed that he has served as a consultant to Negma-Lerads, AstraZeneca, Eisai, and Prometheus.

Professor of Medicine, Stanford University School of Medicine, Palo Alto, California; Chief of Hepatology, Co-Director, Liver Transplant Program, Stanford University Medical Center, Palo Alto, California

Emmet B. Keefe, MD, has disclosed that he has received grants for clinical research from Roche and Romark and received grants for educational acitivies from Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Idenix-Novartis, Roche, and Romark. Dr. Keefe has also disclosed that he has served as an advisor or consultant to Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Idenix-Novartis, Intarcia, Roche, and Romark.

Associate Professor, Dartmouth Medical School, Hanover, New Hampshire; Director, GI Motility Laboratory, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

Director, Center for Inflammatory Bowel Disease, Department of Gastroenterology, The Cleveland Clinic Foundation, Cleveland, Ohio

Bret Lashner, MD, has disclosed that he has served as an advisor or consultant to Elan, Shire, Abbott, Prometheus, UCB, and Proctor and Gamble.

Associate Professor of Medicine; Director, Center for Inflammatory Bowel Diseases, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Gary R. Lichtenstein, MD, has disclosed that he has received grants for clinical research from the following companies: Abbott Corporation; Berlex; Celgene; Celltech, Inc.; Centocor, Inc.; Genetics Institute; Inkine, Inc.; Intesco Corporation; ISIS Corporation; Millennium Pharmaceuticals; Otsuka Corporation; Protein Design Labs; Protomed Scientific; and Salix Pharmaceuticals. Dr. Lichtenstein has also disclosed that he has served as a consultant to the following companies: Abbott Corporation; AstraZeneca, Inc.; Axcan Corporation; Bristol-Myers Squibb; Celltech Inc.; Centocor, Inc.; Elan; Faro Pharmaceuticals; GlaxoSmithKline; Human Genome Sciences; Procter & Gamble; Prometheus Laboratories, Inc.; Protein Design Labs; Protomed Scientific; Salix Pharmaceuticals; Schering-Plough Corporation; Serono; Shire Pharmaceuticals; Solvay Pharmaceuticals; Synta Pharmaceuticals; UCB; and Wyeth. Dr. Lichtenstein has also disclosed that he serves on the speaker's bureaus of the following companies: AstraZeneca, Inc.; Axcan Corporation; Centocor, Inc.; Faro Pharmaceuticals; Procter & Gamble; Salix Pharmaceuticals; Schering-Plough Corporation; Shire Pharmaceuticals; and Solvay Pharmaceuticals. Dr. Lichtenstein has also disclosed that he receives honoraria from Falk Pharmaceuticals.

Professor of Internal Medicine; Executive Vice-President for Clinical Affairs, University of Texas Southwestern Medical Center at Dallas

Willis C. Maddrey, MD, has disclosed that he has served as a consultant to GlaxoSmithKline, Schering, Idun, Isis, Bristol-Myers Squibb, Pfizer, Idenix, and Intarcia.

Professor of Medicine, Associate Director of the Division of Liver Disease, Recanati/Miller Transplantation Institute, Mount Sinai Hospital, New York, NY

Paul Martin, MD, has disclosed that has received grants for clinical research and for educational activities from Roche, Schering, Bristol-Myers Squibb, Gilead, and Idenix. Dr. Martin has also disclosed that he has served as an advisor or consultant to Roche, Schering, Bristol-Myers Squibb, Gilead, and Idenix.

Associate Professor, Department of Surgery, University of Washington, Seattle; Associate Professor, Department of Surgery; Director, The Swallowing Center, University of Washington Medical Center, Seattle, Washington

Brant K. Oelschlager, MD, has disclosed no relevant financial relationships.

Professor of Medicine, Indiana University School of Medicine, Indianapolis, Indiana; Director of Endoscopy, Indiana University Hospital, Indianapolis, Indiana

Douglas K. Rex, MD, FACG, has disclosed that he has received research support from Olympus, CB Fleet, Salix, MGI Pharma, and Given Imaging. Dr. Rex has also disclosed that he has served as a member of Scientific Advisory Boards for Given Imaging, Avantis, Neo Guide, CB Fleet, Salix, GI View, MGI Pharma and has served on speaker's bureaus for TAP, Novartis, CB Fleet, Salix, and Olympus.

Assistant Professor of Medicine, Geffen UCLA School of Medicine, Los Angeles, California; Medical Director, Liver Transplant Program, Cedars-Sinai Medical Center, Los Angeles, California

Tram T. Tran, MD, has disclosed that she has received grants for educational activities from and served as an advisor or consultant to Schering-Plough, Bristol-Myers Squibb, Gilead Sciences, Idenix, and Novartis.